VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

por Yu, Tengteng, Chaganty, Bharat, Lin, Liang, Xing, Lijie, Ramakrishnan, Boopathy, Wen, Kenneth, Hsieh, Phillip A., Wollacott, Andrew, Viswanathan, Karthik, Adari, Hedy, Cho, Shih-Feng, Li, Yuyin, Chen, Hailin, Yang, Wenjuan, Xu, Yan, An, Gang, Qiu, Lugui, Munshi, Nikhil, Babcock, Gregory, Shriver, Zachary, Myette, James R., Anderson, Kenneth C., Tai, Yu-Tzu
Publicado 2020